Mobile

Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carci...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013222-16

Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Part A The primary study objective is to assess the efficacy of repeated s.c. injections at different doses of BIM 23A760 on patient’s overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment. Part B The primary objective is to assess the long term safety of weekly injections of BIM 23A760 in patients with carcinoid syndrome.

Critère d'inclusion

  • Carcinoid Syndrome

Liens